Itorax
Itorax Uses, Dosage, Side Effects, Food Interaction and all others data.
Itorax is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.
Trade Name | Itorax |
Generic | Itopride |
Itopride Other Names | Itopride |
Weight | 50mg |
Type | Tablet |
Formula | C20H26N2O4 |
Weight | Average: 358.4314 Monoisotopic: 358.18925733 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | Tas Med India Pvt Ltd |
Available Country | India |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Itorax is an acetylcholine esterase inhibitor and dopamine D2 receptor antagonist used to treat symptoms of functional dyspepsia such as nausea and vomiting.
Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).
Itorax is also used to associated treatment for these conditions: Abdominal Pain, Dyspepsia, Functional Dyspepsia, Gastroenteritis, Loss of Appetite, Nausea, Nausea and vomiting, Vomiting, Abdominal bloating, Pyrosis, Stomach discomfort
How Itorax works
Itorax has anticholinesterase (AchE) activity as well as dopamine D2 receptor antagonistic activity. It is well established that M3 receptors exist on the smooth muscle layer throughout the gut and acetylcholine (ACh) released from enteric nerve endings stimulates the contraction of smooth muscle through M3 receptors. The enzyme AChE hydrolyses the released ACh, inactivates it and thus inhibits the gastric motility leading to various digestive disorders. Besides ACh, dopamine is present in significant amounts in the gastrointestinal tract and has several inhibitory effects on gastrointestinal motility, including reduction of lower esophageal sphincter and intragastric pressure. These effects appear to result from suppression of ACh release from the myenteric motor neurons and are mediated by the D2 subtype of dopamine receptors. Itorax, by virtue of its dopamine D2 receptor antagonism, removes the inhibitory effects on Ach release. It also inhibits the enzyme AchE which prevents the degradation of ACh. The net effect is an increase in ACh concentration, which in turn, promotes gastric motility, increases the lower esophageal sphincter pressure, accelerates gastric emptying and improves gastro-duodenal coordination. This dual mode of action of Itorax is unique and different from the actions of other prokinetic agents available in the market.
Innovators Monograph
You find simplified version here Itorax